HROW MEXC RealStocks
Own real HROW shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-16 11:28:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Harrow, Inc. (HROW) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $30.00, with a market capitalization of $1.13B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $25.76 to $54.85. This page covers its latest market performance, valuation, price trends and company information.
$1.13B | |
$30.30 | |
$30.30 | |
$29.96 | |
$30.12 | |
-- | |
620.91K | |
-- | |
$54.85 | |
$25.76 | |
-- | |
-- |
Harrow, Inc. (HROW) is trading at $30.00 in pre-market trading as of 2026-11-16 09:36:00, down 0.39% ($0.12) from the previous close of $30.12
Pre-market trading shows how investors are pricing HROW before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Harrow, Inc. (HROW) moved from $26.04 to $30.00, representing a gain of 15.22% ($3.96).
The stock traded between $25.76 and $33.68 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 992.01 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 14.6%
HROW is currently trading at $30.00, placing it 14.6% of the way from its 52-week low of $25.76 to its 52-week high of $54.85. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 373 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Harrow, Inc. (HROW) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to HROW, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between HROW shares and USD.
HROW Shares to USD
1.00 HROW shares = 30.004 USD
Calculations are estimates based on the latest available price and are for reference only.